Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Capital One Financial Corp. (COF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Capital One Financial Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.48 (market cap $29.60B), while Capital One Financial Corp. trades at $221.17 (market cap $134.45B). The key difference: Capital One Financial Corp. is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Capital One Financial Corp. pays a 1.46% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | COF | |
|---|---|---|
Market Cap | $29.60B | $134.45B |
Sector | Health | Financials |
52-Week High | $491.22 | $257.94 |
52-Week Low | $205.48 | $176.10 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Capital One Financial (COF) trades at $221.20, up 1.02% today, with a bullish technical signal from moving averages but overbought RSI readings near 77. The stock shows strong fundamentals with a P/E of 12.07 and net income margin of 16.96% for 2026, supported by robust Q2 2026 earnings beating estimates. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.
Outlook is positive with a consensus price target of $251.60, implying 14% upside, driven by earnings growth and synergy capture from Discover. Key risks include integration execution, credit loss provisions, and economic sensitivity. The bullish analyst consensus (63% Buy) and institutional holdings suggest confidence in continued performance, though overbought conditions may prompt near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
